{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:07:13Z","timestamp":1782950833497,"version":"3.54.5"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"6","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2020,9,17]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>In Part 1 of this Thematic Issue entitled \u201cSystemic Autoimmune Rheumatic Diseases and Cardiology\u201d, a\npanel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular\ncomplications of spondyloarthritides, rheumatoid arthritis, Sjogren\u2019s syndrome and vasculitides, as well as relevant cardiovascular\nissues related to non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), and provided\ntheir recommendations for prevention and management of these complications. In part 2 of this Thematic Issue, experts\ndiscuss the enhanced cardiovascular risk conferred by additional autoimmune rheumatic diseases (ARDs), including systemic\nlupus erythematosus, the antiphospholipid syndrome, psoriasis and psoriatic arthritis and juvenile idiopathic arthritis.\nThese, and the previous articles, place inflammation as the key common link to explain the enhanced risk of cardiovascular\ncomplications in patients with ARDs. It follows that treatment should probably target inflammation. From all\nthese contemporary reviews, the conclusion that is derived further supports the notion of the emerging field of Cardio-\nRheumatology where physicians and experts from these two disciplines collaborate in risk stratification and optimization\nof preventive strategies and drug therapies in patients with ARDs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161118666200721145718","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T06:15:24Z","timestamp":1595398524000},"page":"533-537","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases"],"prefix":"10.2174","volume":"18","author":[{"given":"Antonis S.","family":"Manolis","sequence":"first","affiliation":[{"name":"Third Department of Cardiology, Athens University School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Athens University School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"k1036","DOI":"10.1136\/bmj.k1036","volume":"361","author":"England B.R.","year":"2018","unstructured":"England B.R.; Thiele G.M.; Anderson D.R.; Mikuls T.R.; Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018,361,k1036","journal-title":"BMJ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.autrev.2017.12.001","volume":"17","author":"Lee K.S.","year":"2018","unstructured":"Lee K.S.; Kronbichler A.; Eisenhut M.; Lee K.H.; Shin J.I.; Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. Autoimmun Rev 2018,17(3),201-214","journal-title":"Autoimmun Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11883-015-0497-6","volume":"17","author":"Mankad R.","year":"2015","unstructured":"Mankad R.; Atherosclerotic vascular disease in the autoimmune rheumatologic patient. Curr Atheroscler Rep 2015,17(4),497","journal-title":"Curr Atheroscler Rep"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/1570161118666200129125320","volume":"18","author":"Melissaropoulos K.","year":"2020","unstructured":"Melissaropoulos K.; Bogdanos D.; Dimitroulas T.; Sakkas L.I.; Kitas G.D.; Daoussis D.; Primary sj\u00f6gren\u2019s syndrome and cardiovascular disease. Curr Vasc Pharmacol 2020,18(5),447-454","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1570161117666190619143842","volume":"18","author":"Fragoulis G.E.","year":"2019","unstructured":"Fragoulis G.E.; Panayotidis I.; Nikiphorou E.; Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 2019,18(5),431-446","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/1570161118666200130093432","volume":"18","author":"Soulaidopoulos S.","year":"2020","unstructured":"Soulaidopoulos S.; Madenidou A.V.; Daoussis D.; Cardiovascular disease in the systemic vasculitides. Curr Vasc Pharmacol 2020,18(5),463-472","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/1570161117666190426164306","volume":"18","author":"Papagoras C.","year":"2019","unstructured":"Papagoras C.; Voulgari P.; Drosos A.; Cardiovascular disease in the spondyloarthritides. Curr Vasc Pharmacol 2019,18(5),473-487","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/1570161117666190930113837","volume":"18","author":"Mourouzis I.S.","year":"2019","unstructured":"Mourouzis I.S.; Manolis A.S.; Pantos C.; Cardiovascular risk of synthetic, non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Curr Vasc Pharmacol 2019,18(5),455-462","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/1570161118666200214115532","volume":"18","author":"Drakopoulou M.","year":"2020","unstructured":"Drakopoulou M.; Soulaidopoulos S.; Oikonomou G.; Toutouzas K.; Tousoulis D.; Cardiovascular effects of biologic disease-modifying anti-rheumatic drugs (DMARDs). Curr Vasc Pharmacol 2020,18(5),488-06","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/1570161118666200127142936","volume":"18","author":"Atzeni F.","year":"2020","unstructured":"Atzeni F.; Nucera V.; Gerratana E.; Cardiovascular consequences of autoimmune rheumatic diseases. Curr Vasc Pharmacol 2020,18(6),566-579","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2174\/1570161118666191227101636","volume":"18","author":"Kostopoulou M.","year":"2020","unstructured":"Kostopoulou M.; Nikolopoulos D.; Parodis I.; Bertsias G.; Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol 2020,18(6),549-565","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2174\/1570161117666190830101341","volume":"18","author":"Polytarchou K.","year":"2020","unstructured":"Polytarchou K.; Varvarousis D.; Manolis A.S.; Cardiovascular Disease in antiphospholipid syndrome. Curr Vasc Pharmacol 2020,18(6),538-548","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1570161118666200523154318","volume":"18","author":"Kapniari E.","year":"2020","unstructured":"Kapniari E.; Papadimitriou P.; Dalamaga M.; Investigating the link between psoriasis and cardiovascular disease: current evidence, therapeutic implications and perspectives. Curr Vasc Pharmacol 2020,18(6),592-609","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2174\/1570161118666200408121307","volume":"18","author":"Arsenaki E.","year":"2020","unstructured":"Arsenaki E.; Georgakopoulos P.; Mitropoulou P.; Cardiovascular disease in Juvenile Idiopathic Arthritis. Curr Vasc Pharmacol 2020,18(6),580-591","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"Agca R.","year":"2017","unstructured":"Agca R.; Heslinga S.C.; Rollefstad S.; EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 2017,76(1),17-28","journal-title":"Ann Rheum Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.hjc.2018.01.008","volume":"60","author":"Ntusi N.A.B.","year":"2019","unstructured":"Ntusi N.A.B.; Francis J.M.; Gumedze F.; Cardiovascular magnetic resonance characterization of myocardial and vascular function in rheumatoid arthritis patients. Hellenic J Cardiol 2019,60(1),28-35","journal-title":"Hellenic J Cardiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fmed.2018.00026","volume":"5","author":"Atzeni F.","year":"2018","unstructured":"Atzeni F.; Corda M.; Gianturco L.; Porcu M.; Sarzi-Puttini P.; Turiel M.; Cardiovascular imaging techniques in systemic rheumatic diseases. Front Med (Lausanne) 2018,5,26","journal-title":"Front Med (Lausanne)"},{"key":"ref=18","first-page":"195","volume":"7","author":"Manolis A.S.","year":"2012","unstructured":"Manolis A.S.; Manolis T.A.; Melita H.; Atherosclerosis: an athero-thrombo-inflammatory disease. Hosp Chron 2012,7(4),195-201","journal-title":"Hosp Chron"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/08830185.2018.1539084","volume":"38","author":"Manolis A.A.","year":"2019","unstructured":"Manolis A.A.; Manolis T.A.; Melita H.; Manolis A.S.; Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol 2019,38(1),33-54","journal-title":"Int Rev Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MOL.0000000000000620","volume":"30","author":"Mackey R.H.","year":"2019","unstructured":"Mackey R.H.; Kuller L.H.; Moreland L.W.; Inflammatory joint diseases and atherosclerosis: time to look beyond the \u2018lipid paradox\u2019. Curr Opin Lipidol 2019,30(4),342-349","journal-title":"Curr Opin Lipidol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1570161118666200514222236","volume":"18","author":"Manolis A.S.","year":"2020","unstructured":"Manolis A.S.; Tzioufas A.G.; Cardio-rheumatology: cardiovascular complications in systemic autoimmune rheumatic diseases is inflammation the common link and target? Curr Vasc Pharmacol 2020,18(5),425-430","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/art.21954","volume":"54","author":"Stea E.A.","year":"2006","unstructured":"Stea E.A.; Routsias J.G.; Clancy R.M.; Buyon J.P.; Moutsopoulos H.M.; Tzioufas A.G.; Anti-La\/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006,54(7),2228-2234","journal-title":"Arthritis Rheum"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tcm.2019.06.006","volume":"30","author":"Manolis A.A.","year":"2020","unstructured":"Manolis A.A.; Manolis T.A.; Melita H.; Manolis A.S.; Congenital heart block: Pace earlier (Childhood) than later (Adulthood). Trends Cardiovasc Med 2020,30(5),275-286","journal-title":"Trends Cardiovasc Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/bph.14604","volume":"176","author":"Taylor E.B.","year":"2019","unstructured":"Taylor E.B.; Wolf V.L.; Dent E.; Ryan M.J.; Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol 2019,176(12),1897-1913","journal-title":"Br J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrcardio.2017.118","volume":"15","author":"Bartoloni E.","year":"2018","unstructured":"Bartoloni E.; Alunno A.; Gerli R.; Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol 2018,15(1),33-44","journal-title":"Nat Rev Cardiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/OARRR.S157229","volume":"10","author":"Sule S.","year":"2018","unstructured":"Sule S.; Fontaine K.; Metabolic syndrome in adults with a history of juvenile arthritis. Open Access Rheumatol 2018,10,67-72","journal-title":"Open Access Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12969-018-0302-5","volume":"16","author":"Aulie H.A.","year":"2018","unstructured":"Aulie H.A.; Estensen M.E.; Selvaag A.M.; Lilleby V.; Flat\u00f8 B.; Aakhus S.; Arterial properties in adults with long-lasting active juvenile idiopathic arthritis compared to healthy controls. Pediatr Rheumatol Online J 2018,16(1),85","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/03009742.2015.1126345","volume":"45","author":"Anderson J.H.","year":"2016","unstructured":"Anderson J.H.; Anderson K.R.; Aulie H.A.; Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. Scand J Rheumatol 2016,45(4),299-303","journal-title":"Scand J Rheumatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00296-016-3534-z","volume":"37","author":"Koca B.","year":"2017","unstructured":"Koca B.; Sahin S.; Adrovic A.; Barut K.; Kasapcopur O.; Cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int 2017,37(1),137-142","journal-title":"Rheumatol Int"},{"key":"ref=30","first-page":"796","volume":"31","author":"Raab A.","year":"2013","unstructured":"Raab A.; Sengler C.; Niewerth M.; Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register. Clin Exp Rheumatol 2013,31(5),796-802","journal-title":"Clin Exp Rheumatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/CS20090557","volume":"118","author":"Van der Heiden K.","year":"2010","unstructured":"Van der Heiden K.; Cuhlmann S.; Luong A.; Zakkar M.; Evans P.C.; Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 2010,118(10),593-605","journal-title":"Clin Sci (Lond)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar3324","volume":"13","author":"van Loo G.","year":"2011","unstructured":"van Loo G.; Beyaert R.; Negative regulation of NF-\u03baB and its involvement in rheumatoid arthritis. Arthritis Res Ther 2011,13(3),221","journal-title":"Arthritis Res Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/ar2457","volume":"10","author":"Brown K.D.","year":"2008","unstructured":"Brown K.D.; Claudio E.; Siebenlist U.; The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008,10(4),212","journal-title":"Arthritis Res Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrcardio.2014.206","volume":"12","author":"Prasad M.","year":"2015","unstructured":"Prasad M.; Hermann J.; Gabriel S.E.; Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015,12(3),168-176","journal-title":"Nat Rev Cardiol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184012\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T15:42:06Z","timestamp":1609774926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184012\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161118666200721145718","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}